4-氯-2-氰基苯甲酸甲酯 | 58331-97-8

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-2-氰基苯甲酸甲酯
• 英文名称: 4-chloro-2-cyanobenzoic acid methyl ester
• 英文别名: 4-chloro-2-cyanobenzoic acid, methyl ester；4-chloro-2-cyanobenzoic acid,methyl ester；methyl 4-chloro-2-cyanobenzoate；4-Chlor-2-cyano-benzoesaeuremethylester
• CAS: 58331-97-8
• 化学式: C₉H₆ClNO₂
• mdl: MFCD08234732
• 分子量: 195.605
• InChiKey: JKAWTBOCEPQPBQ-UHFFFAOYSA-N

物化性质

• 熔点：
  115-117 °C
• 沸点：
  305.8±27.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氯-2-氰基苯甲酸甲酯 在 氨 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 73.17h， 生成 cyano-(6-chloro-2,3-dihydro-2-methyl-3-oxoisoindol-1-ylidene)acetic acid ethyl ester
  参考文献：
  名称：

  Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents

  摘要：

  Compounds from two novel series of spirosuccinimides were prepared. Analogs of series 2 possessed a spiro-fused isoindolone moiety while those of series 3 contained a spiro-fused benzisothiazole S,S-dioxide group. These compounds were evaluated as aldose reductase inhibitors (ARI) in vitro by their ability to inhibit glyceraldehyde reduction using a partially purified bovine lens aldose reductase preparation and in vivo as inhibitors of galactitol accumulation in the lens, sciatic nerve, and diaphragm of galactose-fed rats. Many members from the isoindolone series 2, particularly those containing an isoindolone N-methyl moiety, showed good in vitro and in vivo potency. The most potent member, the 6-chloro analog 32, was resolved, and aldose reductase activity was found to reside almost exclusively in the (+)-enantiomer. Compound 32 was approximately equipotent in the sciatic nerve of the galactose-fed rat to other cyclic imide ARI's of similar in vitro activity, namely sorbinil and ADN-138 and also to tolrestat, an acetic acid-based ARI (ED50's 4-8 mg/kg). Compounds from both series, 2 and 3, were also found to lower plasma glucose levels of genetically obese db/db and ob/ob mice with potency similar to that of ciglitazone. However, members from these series failed to lower insulin levels of the ob/ob mouse at the doses tested.

  DOI：

  10.1021/jm00102a016
• 作为产物：
  描述：

  甲基2-胺-4-氯苯酚酯 生成 4-氯-2-氰基苯甲酸甲酯
  参考文献：
  名称：

  WROEL, JAY E.

  摘要：

  DOI：

文献信息

• MST1 KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Augeri David John

  公开号：US20120225857A1

  公开（公告）日：2012-09-06

  Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.

  揭示了用于抑制哺乳动物Ste20样激酶1（MST1）的化合物，以及包含它们的组合物和在治疗、管理或预防炎症性或自身免疫疾病或紊乱中使用它们的方法。
• Novel spirosuccinimides as aldose reductase inhibitors and
  申请人：American Home Products Corp.

  公开号：US04900739A1

  公开（公告）日：1990-02-13

  This invention relates to novel spirosuccinimide derivatives, to the processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties which render them beneficial for the treatment of diabetes mellitus and associated conditions.

  这项发明涉及新型螺环琥酰亚胺衍生物，其制备方法，化合物的使用方法以及其药物制剂。这些化合物具有药理特性，使它们对于治疗糖尿病及相关症状具有益处。
• MST1 kinase inhibitors and methods of their use
  申请人：Augeri David John

  公开号：US08440652B2

  公开（公告）日：2013-05-14

  Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders. Particular compounds are of the formula:

  本发明揭示用于抑制哺乳动物Ste20样激酶1（MST1）的化合物，以及包含它们的组合物和在治疗、管理或预防炎症或自身免疫疾病或紊乱方面使用它们的方法。特定的化合物的公式为：
• Tank-binding kinase inhibitor compounds
  申请人：Gilead Sciences, Inc.

  公开号：US10316049B2

  公开（公告）日：2019-06-11

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  公开了具有下式（I）的化合物及其使用和制备方法：
• [EN] 1,5-DIHYDRO-2,4-BENZODIAZEPINE-3-ONE DERIVATIVE AND APPLICATION THEREOF<br/>[FR] DÉRIVÉ DE 1,5-DIHYDRO-2,4-BENZODIAZÉPINE-3-ONE ET SON UTILISATION<br/>[ZH] 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用
  申请人：NHWA PHARMA CORP

  公开号：WO2021218863A1

  公开（公告）日：2021-11-04

  本发明涉及化学医药领域，尤其涉及1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用，本发明提供的1,5-二氢-2,4-苯二氮䓬-3-酮衍生物如式I所示化合物，作用于5-HT2A、5-HT2C受体，对5-HT2A的选择性优于或与哌吗色林类似。用于治疗精神分裂症或者帕金森氏病、痴呆症相关的行为紊乱及精神病。本申请化合物抗精神病活性与哌吗色林相当，镇静副作用、运动恶化副作用小于哌吗色林,且心脏毒性小于哌吗色林。